OaxaCannabis

11/07/2026

25/06/2026

https://www.youtube.com/watch?v=ZBNg9WIc-vQ&t=2s

Hamilton investigates the biology and clandestine cultivation of ps...

23/06/2026

https://www.facebook.com/photo/?fbid=1450543167119425&set=a.634822885358128

Rick Strassman is best known for conducting government approved human studies on DMT in the 1990s. During those studies, many participants reported encountering seemingly intelligent beings, entities, or presences while under the influence of DMT. Some described them as elves, guides, aliens, spirits, or other autonomous intelligences that appeared more real than ordinary waking reality.

Strassman became intrigued by the fact that so many participants independently reported similar encounters. Over time, he moved away from viewing DMT experiences as purely hallucinations and began exploring whether they might represent access to other levels of consciousness or aspects of reality not yet understood by science.

A growing group of researchers, philosophers, and consciousness theorists have come to think that many users report encounters with intelligent entities that seem autonomous and independent of their own thoughts. Another is that people from different cultures sometimes describe surprisingly similar types of beings despite having no prior connection to one another.

Some researchers have proposed what is sometimes called the "receiver" or "filter" hypothesis. Instead of the brain creating consciousness, the brain may filter a much larger field of consciousness. Under this view, DMT temporarily alters the filter, allowing awareness to access information or dimensions normally hidden from everyday perception.

Strassman's own position has become more nuanced over the years. He has suggested that materialist explanations of reality may be incomplete, but he has also acknowledged that there is currently no definitive evidence proving that DMT entities are external intelligences. The experiences are undeniably real to the people having them. Whether the beings exist independently of the mind remains an open question.

If thousands of people report encounters with seemingly autonomous intelligences in a consistent way, are those experiences merely brain-generated imagery, or do they point toward aspects of consciousness that science has not yet learned how to measure? This is the question they are exploring.

23/06/2026

(English below)
Estos resultados ponen de relieve la diversidad bioquímica del Cannabis sativa cultivado en el estado de Ondo (Nigeria) y su potencial como fuente de nutrientes y compuestos bioactivos, con una gran variabilidad entre los distintos tejidos vegetales. Su riqueza en antioxidantes, especialmente en las hojas y el tallo, sugiere posibles aplicaciones en las industrias nutracéutica, de alimentos funcionales y farmacéutica. Estos resultados aportan datos valiosos para la utilización segura y la valorización del Cannabis sativa como planta medicinal polivalente.

https://www.researchsquare.com/article/rs-9281008/v1

A study on the biochemical diversity of cannabis grown in Ondo State (Nigeria) and its potential as a source of nutrients and bioactive compounds suggests possible applications in the nutraceutical, functional food and pharmaceutical industries.
These findings highlight the biochemical diversity of Cannabis sativa cultivated in Ondo state, Nigeria and its potential as a source of nutrients and bioactive compounds, with high variability across different plant tissues. Its antioxidant richness, especially in the composite and stem, suggests potential applications in the nutraceutical, functional food, and pharmaceutical industries. These findings contribute valuable data toward the safe utilization and valorization of Cannabis sativa as a multipurpose medicinal plant.

21/06/2026

Aprovechamiento de los cannabinoides para tratar la inflamación y el estrés oxidativo en la medicina traslacional.
La inflamación y el estrés oxidativo contribuyen a numerosas enfermedades humanas. Las terapias convencionales proporcionan un alivio sintomático, pero no logran abordar la disfunción molecular. Los cannabinoides se perfilan como moduladores prometedores de estos procesos.

https://jintb.org/index.php/jintb/article/view/30

Harnessing Cannabinoids to Target Inflammation and Oxidative Stress in Translational Medicine.
Inflammation and oxidative stress contribute to numerous human diseases. Conventional therapies provide symptomatic relief but fail to address molecular dysfunction. Cannabinoids emerge as promising modulators of these processes.
By bringing mechanistic insights with clinical application, cannabinoids hold significant potential to address diseases driven by inflammation and oxidative stress and to expand therapeutic landscape.

21/06/2026

A new review in Progress in Neuro-Psychopharmacology and Biological Psychiatry argues psilocybin, L*D, and DMT could target the root neurobiology of autism, not just its symptoms.

Standard ASD drugs like risperidone blunt irritability but leave social and cognitive rigidity untouched.

The case rests on three mechanisms.

1. Plasticity: ASD may involve critical learning windows that close too early, locking rigid circuits in before social skills fully develop. Psychedelics, via 5-HT2A activation, trigger a cascade, glutamate, BDNF, mTOR, that reopens juvenile-like plasticity.

2. Inflammation: ASD brains show chronic neuroinflammation that suppresses plasticity; psychedelics may shift 5-HT2A signalling toward anti-inflammatory pathways.

3. Prediction: Under the REBUS (Relaxed Beliefs Under Psychedelics) model, ASD involves overly rigid top-down priors; psychedelics loosen them, opening a window for revising entrenched patterns.

Evidence is mostly preclinical. One small M**A trial found reduced anxiety in 12 autistic adults. The PSILAUT psilocybin trial is ongoing, due later in 2026.

Source: Source: Low, Z.X.B. et al. (2026). Serotonergic psychedelics for Autism Spectrum Disorder: Neurobiological mechanisms and translational prospects. Progress in Neuro-Psychopharmacology and Biological Psychiatry DOI: 10.1016/j.pnpbp.2026.111717

09/06/2026

Un equipo de investigadores desarrolló un termoplástico llamado polycannabidiol carbonate, fabricado a partir de CBD extraído de biomasa de cáñamo, un termoplástico 92% bio-based que presenta propiedades similares a las de plásticos derivados del petróleo.
Publicado en la revista Chem Circularity de Cell Press, este avance no solo promete una alternativa sostenible al PET y al BPA, sino que introduce un material con capacidades extraordinarias.
La clave del avance está en entender al CBD como algo más que un cannabinoide. En este caso, los investigadores lo usan como monómero; es decir, como una unidad molecular capaz de unirse a otras unidades para formar largas cadenas: polímeros.

https://elplanteo.com/plasticos-cbd-canamo-pcbdc/

A team of researchers has developed a thermoplastic called polycannabidiol carbonate, made from CBD extracted from h**p biomass; this 92% bio-based thermoplastic exhibits properties similar to those of petroleum-derived plastics.
Published in Cell Press’s journal Chem Circularity, this breakthrough not only promises a sustainable alternative to PET and BPA, but also introduces a material with extraordinary capabilities.
The key to the breakthrough lies in understanding CBD as more than just a cannabinoid. In this case, the researchers use it as a monomer; that is, as a molecular unit capable of bonding with other units to form long chains: polymers.

29/05/2026

A landmark systematic review and meta-analysis published in The Lancet Psychiatry has challenged a rapidly growing sector of modern medicine.

Led by Dr. Jack Wilson at the University of Sydney’s Matilda Centre, the research found no high-quality clinical evidence indicating that medicinal cannabis effectively treats anxiety, depression, or post-traumatic stress disorder (PTSD)—the primary psychiatric conditions for which it is routinely prescribed.

Evaluating 54 randomized controlled trials spanning 45 years of clinical data, the comprehensive study revealed that cannabinoids, including both cannabidiol (CBD) and tetrahydrocannabinol (THC) formulations, failed to outperform placebos in reducing core psychological symptoms.

While medicinal cannabis sales and prescription approvals have tripled over the past four years, the findings expose a stark divergence between public perception and rigorous scientific reality, suggesting that the popular narrative of cannabis as a mental health "cure-all" is largely unsupported by data.

Beyond the lack of proven psychiatric efficacy, researchers raised concerns regarding potential secondary clinical risks.

Although the acute data showed cannabis to be relatively safe over short periods, long-term or chronic use—particularly of high-THC products—carries a well-documented risk of worsening baseline mental health outcomes.

This includes an elevated probability of developing cannabis use disorder (dependency), inducing psychotic symptoms in vulnerable populations, and critically delaying patient access to proven, first-line evidence-based interventions like cognitive behavioral therapy (CBT).

29/05/2026

Este caso respalda el papel potencial de la combinación de aceites de cannabis ricos en THC y ricos en CBD como complemento seguro y eficaz en el tratamiento paliativo multimodal de caballos con afecciones crónicas y refractarias.
---
Case Report: Oral and Topical Chronic Administration of THC-Rich and CBD-Rich Cannabis Oil as Palliative Care in a Rescued Horse with Open Wound, Sarcoid and Chronic Pain.
This case supports the potential role of combined THC-rich and CBD-rich cannabis oils as a safe and effective adjunct in multimodal palliative care for horses with chronic, refractory conditions.

https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2026.1794084/abstract